AZD5658 / AstraZeneca, Conduit Pharmaceuticals - LARVOL DELTA

Conduit Pharmaceuticals Expands Partnership with Sarborg Limited to Leverage Machine Learning Data Analysis for Pipeline Optimization (GlobeNewswire) - "Conduit Pharmaceuticals Inc...announces that it has entered into an additional license and use agreement (the 'Additional Agreement') with Sarborg Limited ('Sarborg') to expand the scope of work on Conduit’s acquired AstraZeneca assets, including AZD1656, AZD5658, and AZD5904...Under the agreement, Sarborg will apply its proprietary machine learning algorithms to conduct an in-depth analysis of Conduit’s clinical and safety data, with the goal of uncovering missed insights, identifying potential drug repurposing opportunities, and highlighting gaps in existing datasets. A key focus will be the re-evaluation of historical clinical trial data, including endpoints, to determine whether specific patient subgroups may have demonstrated therapeutic benefits, findings that could refine Conduit’s future clinical development strategy."

Commercial • Immunology • Lupus

Conduit Pharmaceuticals Provides Research and Development Update on Progress for Pipeline Assets AZD1656, AZD5658... (GlobeNewswire) - "Conduit Pharmaceuticals Inc...today provides an R&D update on the development progress of pipeline assets AZD1656, AZD5658...Conduit has partnered with Charles River Laboratories Inc. to conduct preclinical studies evaluating its glucokinase inhibitors towards applications in autoimmune diseases, with an initial focus on lupus...This study is expected to generate critical data on the therapeutic potential, informing future clinical development plans with results anticipated in Q2 2025...In parallel, Conduit continues to optimize the protocol for the design of its Phase II clinical trial for AZD1656...Recent milestones include the grant of a composition-of-matter patent for the AZD1656 Cocrystals by the Japan Patent Office (JPO) and IP Australia...In addition, Conduit is actively working to develop new solid forms of its key assets, including AZD1656...AZD5658."

Clinical protocol • Patent • Pipeline update • Preclinical • Immunology • Lupus • Systemic Lupus Erythematosus

Conduit Pharmaceuticals Enters into Exclusive License Agreement with AstraZeneca for Multiple Assets to Advance Potential First-in-Class Treatments (GlobeNewswire) - "Conduit Pharmaceuticals...today announced that the Company has entered into an agreement with AstraZeneca to exclusively license rights to develop AZD1656 and AZD5658, both HK-4 glucokinase activators, and AZD5904, a myeloperoxidase inhibitor (MPO). AstraZeneca had progressed AZD1656 and AZD5904 through Phase 1 clinical trials....Conduit initially intends to conduct Phase II clinical trials on clinical candidates AZD1656 and AZD5658 in 2024 for applications in autoimmune disorders...Under the terms of the License Agreement, AstraZeneca will grant Conduit an exclusive license to both AZD1656 and AZD5658 for all human indications..."

Licensing / partnership • New P2 trial • Immunology